Call me a sceptic but let me split that statement out and comment.
1. The PROMISE of Anisina is that it is not a drug limited to working in a proportion of patients with a particular form of cancer, or one that is reliant on the over-expression of certain functions such as immune checkpoints or pro-survival mechanisms.
2. Its PROMISE lies in its ability to make the most widely-used chemotherapy drugs work better and safer in more forms of cancer and in more patients.
3. Our OBJECTIVE is to see Anisina become one of the most widely used drugs in chemotherapy."
1 and 2 carries the risk of pending trials resuts and subsequent reviews and approvals.
3 carries the risk of the company being able to get a final product market where it secures substantial market share and footprint and profitable revenue streams.
NRT is lucky in that it already has profitable revenue from other products to carry it through the gestation period whilst this product is in development, refinement and subject to approvals, final production and distribution.
Cheers.
P.S. Wonder where CB is on this one...
NRT Price at posting:
20.5¢ Sentiment: None Disclosure: Not Held
